Last reviewed · How we verify

NCT06599931: CERSTIM

Cerebello-motor Neuromodulation After Stroke. CERSTIM.

Recruiting now NA Last updated 16 April 2026
What this trial tests

NA trial testing tACS Transcranial alternating stimulation in Stroke in 45 participants. Currently enrolling.

Timeline
13 December 2024
Primary endpoint
30 January 2027
30 December 2027

Quick facts

Lead sponsorInstitut National de la Santé Et de la Recherche Médicale, France
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposebasic science
Enrollment45
Start date13 December 2024
Primary completion30 January 2027
Estimated completion30 December 2027
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

18 and older, any sex, with Stroke or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CERSTIM study is a physiopatholgical study investigating transcranial alternating current stimulation in stroke patients in the cerebello-motor loop. The design is a cross over design testing two frequencies in the gamma band and one placebo. We will use behavioural data, functional MRI, and Electroencephalography to disentangle the effect of tACS and its frequency. Healthy participants will be also recruited.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Institut National de la Santé Et de la Recherche Médicale, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06599931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing